Clear Street downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $54, up from $49, following Novo Nordisk’s (NVO) plan to acquire Akero for $4.7B upfront, equivalent to about $54 per share.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO: